Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

NCT03110380 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: B/F/TAF
DRUG: F/TAF
DRUG: DTG
DRUG: DTG Placebo
DRUG: F/TAF Placebo
DRUG: B/F/TAF Placebo

Sponsor

Gilead Sciences